152 related articles for article (PubMed ID: 17605341)
1. Chemotherapeutic treatment of xenograft Spirocerca lupi-associated sarcoma in a murine model.
Stettner N; Ranen E; Dank G; Lavy E; Brenner O; Harmelin A
Comp Med; 2007 Jun; 57(3):267-71. PubMed ID: 17605341
[TBL] [Abstract][Full Text] [Related]
2. Murine xenograft model of Spirocerca lupi-associated sarcoma.
Stettner N; Ranen E; Dank G; Lavy E; Aroch I; Harrus S; Brenner O; Harmelin A
Comp Med; 2005 Dec; 55(6):510-4. PubMed ID: 16422146
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
[TBL] [Abstract][Full Text] [Related]
4. Pegylated liposomal doxorubicin as a chemotherapeutic agent for treatment of canine transmissible venereal tumor in murine models.
Stettner N; Brenner O; Eilam R; Harmelin A
J Vet Med Sci; 2005 Nov; 67(11):1133-9. PubMed ID: 16327225
[TBL] [Abstract][Full Text] [Related]
5. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.
Saucier JM; Yu J; Gaikwad A; Coleman RL; Wolf JK; Smith JA
J Oncol Pharm Pract; 2007 Mar; 13(1):39-45. PubMed ID: 17621566
[TBL] [Abstract][Full Text] [Related]
6. A cannabinoid anticancer quinone, HU-331, is more potent and less cardiotoxic than doxorubicin: a comparative in vivo study.
Kogan NM; Schlesinger M; Peters M; Marincheva G; Beeri R; Mechoulam R
J Pharmacol Exp Ther; 2007 Aug; 322(2):646-53. PubMed ID: 17478614
[TBL] [Abstract][Full Text] [Related]
7. Development of an intramuscular xenograft model of canine osteosarcoma in mice for evaluation of the effects of radiation therapy.
Coomer AR; Farese JP; Milner R; Taylor D; Salute ME; Rajon DA; Bova FJ; Siemann DW
Am J Vet Res; 2009 Jan; 70(1):127-33. PubMed ID: 19119958
[TBL] [Abstract][Full Text] [Related]
8. Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma.
Hingorani P; Zhang W; Piperdi S; Pressman L; Lin J; Gorlick R; Kolb EA
Cancer Chemother Pharmacol; 2009 Sep; 64(4):733-40. PubMed ID: 19224214
[TBL] [Abstract][Full Text] [Related]
9. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
Wang YD; Hu Y; Zhang L; Huang J; Sun CY
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
[TBL] [Abstract][Full Text] [Related]
10. [Apoptosis-inducing and anti-tumor effect of cyclophosphamide, cisplatin and adriamycin used separately or combined in murine lymphosarcoma LS].
Nikolin VP; Kaledin VI; Baĭmak TIu; Galiamova MR; Popova NA; Voĭtsitskiĭ VE
Vopr Onkol; 2002; 48(2):211-5. PubMed ID: 12227071
[TBL] [Abstract][Full Text] [Related]
11. A chitosan-dipotassium orthophosphate hydrogel for the delivery of Doxorubicin in the treatment of osteosarcoma.
Ta HT; Dass CR; Larson I; Choong PF; Dunstan DE
Biomaterials; 2009 Jul; 30(21):3605-13. PubMed ID: 19345993
[TBL] [Abstract][Full Text] [Related]
12. Erythropoietin modulates the anticancer activity of chemotherapeutic drugs in a murine lung cancer model.
Sigounas G; Sallah S; Sigounas VY
Cancer Lett; 2004 Oct; 214(2):171-9. PubMed ID: 15363543
[TBL] [Abstract][Full Text] [Related]
13. A bioluminescent orthotopic mouse model of human osteosarcoma that allows sensitive and rapid evaluation of new therapeutic agents In vivo.
Comstock KE; Hall CL; Daignault S; Mandlebaum SA; Yu C; Keller ET
In Vivo; 2009; 23(5):661-8. PubMed ID: 19779098
[TBL] [Abstract][Full Text] [Related]
14. Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model.
Mach CM; Mathew L; Mosley SA; Kurzrock R; Smith JA
Anticancer Res; 2009 Jun; 29(6):1895-9. PubMed ID: 19528445
[TBL] [Abstract][Full Text] [Related]
15. The role of p53 in the chemotherapeutic responses to cisplatin, doxorubicin and 5-fluorouracil treatment.
Dart DA; Picksley SM; Cooper PA; Double JA; Bibby MC
Int J Oncol; 2004 Jan; 24(1):115-25. PubMed ID: 14654948
[TBL] [Abstract][Full Text] [Related]
16. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Wang SJ; Liu RS; Lin WJ; Yang CS; Ting G
Anticancer Res; 2009 Jun; 29(6):2111-20. PubMed ID: 19528471
[TBL] [Abstract][Full Text] [Related]
17. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
Shiraga E; Barichello JM; Ishida T; Kiwada H
Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells.
Kubo T; Shimose S; Matsuo T; Sakai A; Ochi M
Cancer Chemother Pharmacol; 2008 Jun; 62(1):111-6. PubMed ID: 17874104
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of milbemycin oxime against pre-adult Spirocerca lupi in experimentally infected dogs.
Kok DJ; Schenker R; Archer NJ; Horak IG; Swart P
Vet Parasitol; 2011 Apr; 177(1-2):111-8. PubMed ID: 21168275
[TBL] [Abstract][Full Text] [Related]
20. Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts.
Zamboni WC; Strychor S; Joseph E; Walsh DR; Zamboni BA; Parise RA; Tonda ME; Yu NY; Engbers C; Eiseman JL
Clin Cancer Res; 2007 Dec; 13(23):7217-23. PubMed ID: 18056203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
